Weight-Based vs Fixed Dosing — Does It Change What You Pay?

Two ways. Most checkpoint inhibitors are now given as a flat dose — the same milligrams for every adult, whatever they weigh. The older method calculates the dose from body weight, in milligrams per kilogram. Both schedules appear in approved labelling and in the regimen listings published by NCCN and ESMO.

Flat dosing arrived later. Population pharmacokinetic modelling showed that drug exposure was broadly similar across a wide range of body weights, so regulators approved fixed doses for several molecules. It also simplifies preparation and removes a calculation step, which matters in a busy day-care unit.

Weight-based dosing did not disappear. Several combination regimens are still written in milligrams per kilogram. Paediatric dosing is always weight-based. Resource-stratified practice in India has kept a close interest in it for one plain reason: where the family pays for the drug itself, milligrams are money.

Which schedule applies to you is set by the indication, the regimen chosen for it, what CDSCO has approved for that use, and your centre’s protocol. It is not set by your preference, and it cannot be set by your budget alone. Your budget is still a legitimate reason to ask which one you are on.

Nothing on this page is a dosing recommendation. Every figure below illustrates how the arithmetic works. The schedule you receive is a clinical decision for your treating oncologist, taken within approved labelling.

The clinical difference is smaller than most families expect. The billing difference can be large, but only for lighter adults, and only in some circumstances. The example schedule below is a common shape used to show the arithmetic; approved schedules differ by molecule and by indication.

Figures illustrate a widely used schedule shape and are not a recommendation for any individual. All cost commentary on this page is indicative only, as of August 2026, and is framed by product class rather than by brand. Immunotherapy is administered as day care at CION centres, so a routine cycle carries no inpatient bed charge.

Sometimes, in centres whose pharmacy is set up for it. Checkpoint inhibitor vials are single-use and preservative-free, so sharing one vial across two patients needs sterile compounding, a documented beyond-use time, and two people on the same molecule in the same session. It is a pharmacy decision, never one a family arranges.

What safe sharing actually requires. Preparation inside a biological safety cabinet or a clean-room admixture unit. Closed-system transfer devices. Strict aseptic technique. A written beyond-use time for the opened vial. And a schedule that puts two suitable patients in the same day-care session. Many centres do not offer it at all. That is a legitimate safety position rather than obstruction, and it is worth hearing it as one.

Dose rounding is the more common version. Rounding a calculated dose to the nearest vial strength, within a small percentage band, is a recognised oncology-pharmacy practice used to reduce waste. Whether it can be applied to your molecule and your dose is decided by the pharmacy together with your oncologist. It is a question worth asking, because it is the mechanism that turns a lighter body weight into an actual saving.

Ask the pharmacy, not the billing counter. Four questions cover it. Is my dose flat or mg/kg? What vial strengths does this molecule come in? Am I charged per vial dispensed or per milligram used? Does this centre operate vial sharing or dose rounding for this drug? A day-care pharmacist can answer all four in a couple of minutes.

Two things never to do. Never ask for a dose below what the regimen specifies in order to save money — under-dosing is not a discount. And never use a drug bought outside the treating centre without that centre’s pharmacy verifying it first: counterfeit checkpoint inhibitors have been reported entering the Indian supply chain, and a cheap vial from an unverified source is the most expensive mistake in this whole subject.

Whether vial sharing or dose rounding is available for a given molecule is a pharmacy-level decision at the centre treating you, and it differs from centre to centre. Ask before the cycle is prepared rather than after the bill is raised.

This is the table the conversation usually skips. It works through a schedule written as 2 mg/kg with a 200 mg flat alternative, supplied in 100 mg vials. Read the last two columns rather than the middle ones — vials are what a pharmacy bills, not milligrams.

On this schedule and this vial size, a weight-based dose removes a whole vial from the bill only below about 50 kg. Between 50 kg and 100 kg it uses fewer milligrams but opens the same two vials, so unless the pharmacy shares vials or rounds the dose, the family pays the same. A different molecule changes the whole picture: on a schedule of 3 mg/kg against a 240 mg flat dose, the two are equal at 80 kg, and smaller vial strengths mean the saving arrives in more places.

Illustrative arithmetic only, as of August 2026. Vial strengths marketed in India change over time and differ by molecule, so confirm both the schedule and the vial size with the pharmacy at the centre treating you. No price is quoted here against any brand or molecule.

1. 1

   Is my dose flat or calculated from my weight?

   Ask for it in writing on the prescription. Everything else follows from the answer.

2. 2

   What vial strengths does this molecule come in?

   Then ask how many vials your dose actually opens. That number, not the milligram figure, is what the bill is built from.

3. 3

   Am I charged per vial dispensed or per milligram used?

   If it is per vial, a lighter body weight may save nothing without a sharing or rounding policy behind it.

4. 4

   Does this centre operate vial sharing or dose rounding?

   Ask the pharmacy directly. Policies differ from centre to centre, and a centre that says no is making a safety judgement, not withholding a favour.

5. 5

   Before the dose, ask about the product

   A domestically manufactured or biosimilar product in the same class usually changes the drug line far more than any dosing adjustment can, and it changes nothing about your schedule. Biosimilar immunotherapy and what it actually saves sets out how that comparison works.

6. 6

   Check scheme cover, then ask for financial counselling

   Aarogyasri, Ayushman Bharat PM-JAY, CGHS, ECHS and ESI publish package ceilings, and state and central relief funds support cancer treatment separately. Eligibility and the applicable package are decided by the scheme and never by the hospital, so cover is never assured — but CM Relief Fund, PM Fund and NGO support for immunotherapy is the route to check before you start. Then ask for an itemised written estimate.

Product choice. Moving from an imported reference product to a domestically manufactured or biosimilar product in the same class typically changes the drug line by far more than any dosing adjustment can. Dosing is a genuine lever for lighter adults. It is the third or fourth one to pull, not the first.

Extended-interval flat dosing is a different lever again. A schedule of 400 mg every six weeks delivers the same milligrams per month as 200 mg every three weeks, so the drug line barely moves. What falls is the number of journeys, day-care visits and days off work. If distance from the centre is the real problem, this is the question to raise rather than the dosing one.

Some costs dosing never touches. Biomarker testing done before the first cycle is already spent. Response-assessment scans follow a time interval rather than a cycle count, and at CION they are coordinated at partner imaging centres rather than owned by us. Pre-cycle blood tests, travel, stay and supportive medicines carry on regardless of how the dose was calculated.

Where families actually find the money. Scheme cover and relief funds first, then employer or insurance cover, then the routes that sit outside the hospital altogether. Treatment expenditure for a specified illness can attract relief under the Income Tax Act, and Section 80DDB and tax relief on immunotherapy costs explains who can claim and what paperwork the claim needs. Where a son or daughter overseas is funding the treatment, paying for a parent’s immunotherapy from abroad covers the practical side of doing that without delays at the day-care counter. And when the gap is still there, crowdfunding for immunotherapy: what actually works is an honest account of that route rather than an encouraging one.

All cost commentary here is indicative only, as of August 2026, and no figure is attached to a brand. Eligibility for any government scheme is decided by that scheme, so nothing on this page should be read as an assurance of cover.

• Section 80DDB and Tax Relief on Immunotherapy Costs — the relief available on treatment expenditure, who can claim it, and the certificate the claim depends on.
• Paying for a Parent’s Immunotherapy From Abroad — how to fund a parent’s cycles from another country without the transfer holding up the next day-care date.
• Crowdfunding for Immunotherapy: What Actually Works — a realistic account of what community fundraising raises for cancer treatment, and what it does not.
• Immunotherapy at CION Cancer Clinics — how CION plans immunotherapy, from candidacy and biomarker testing to day-care delivery and cost conversations.

All cost figures on this page are indicative only, as of August 2026, and are framed by product class rather than by brand. Dosing figures are illustrative arithmetic, not a recommendation. This page is general information and does not replace a consultation. The dose and schedule that are right for you are a decision for you and your treating oncologist.

Nobody will raise dosing cost on your behalf

It is a fair question, and asking it early is what turns it into a real option rather than a regret.